Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

ZEBinix Retention Rate in Epilepsy in Elderly Patients

Authors not listed

Centre Hospitalier Saint Joseph Saint Luc de Lyon · 2019

Abstract

The incidence of provoked and unprovoked seizures is known to increase with advancing age. Eslicarbazepine acetate (ESL) is one of the third generation of antiepileptic drugs (AEDs) that have been developed in the last ten years with a favorable safety profile. ESL is approved in Europe and the USA as adjunctive or monotherapy in adults with partial-onset seizures. Nevertheless, retrospective data in monotherapy condition in the elderly epileptic population are sparse. The aim of the ZEBRE study is to evaluate the efficacy and the safety of ESL in elderly epileptic patients (\> 65 years). The completion of this study will provide crucial information on the most appropriate ESL treatment for elderly patients suffering from partial seizures.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-06 MST

Cite this

APA
Anonymous. (2019). ZEBinix Retention Rate in Epilepsy in Elderly Patients. <em>Centre Hospitalier Saint Joseph Saint Luc de Lyon</em>. https://clinicaltrials.gov/study/NCT04221282
Vancouver
Anonymous. ZEBinix Retention Rate in Epilepsy in Elderly Patients. Centre Hospitalier Saint Joseph Saint Luc de Lyon. 2019.
BibTeX
@misc{anon2019ZEBini, title = {ZEBinix Retention Rate in Epilepsy in Elderly Patients}, author = {Anonymous}, journal = {Centre Hospitalier Saint Joseph Saint Luc de Lyon}, year = {2019}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings